Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation
Alimentary Pharmacology & Therapeutics · 2024-10 · 60 (7) · 940-952
DOI: 10.1111/apt.18199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 07.08.2024. Verfasst von Kuo-Cheng Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ministry of Science and Technology, Taiwan, Taipei Veterans General Hospital, National Science and Technology Council.
Abstract (Originalsprache)
Background
The benefits of HCV eradication on distinct recurrence patterns and long‐term hepatic outcomes in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) remain uncertain. This study aims to assess the impact of HCV eradication on HCC recurrence patterns and long‐term hepatic outcomes after RFA and to identify predictors of recurrence in patients achieving sustained virological response (SVR).
Methods
We retrospectively enrolled 274 patients receiving RFA for HCV‐related HCC, including 73 and 88 patients treated with interferon‐based (IFN) and direct‐acting antivirals (DAA) therapy, respectively. We analysed factors associated with local tumour progression (LTP), distant recurrence, overall survival, and hepatic decompensation.
Results
SVR was achieved in 49.3% of patients undergoing IFN therapy and 93.2% of patients undergoing DAA therapy. HCV eradication was not associated with LTP but significantly correlated with reduced risk of distant recurrence (by DAA: hazard ratio (HR) = 0.449, p = 0.006), overall survival (by IFN: HR = 0.242, p < 0.001; by DAA: HR = 0.274, p < 0.001) and hepatic decompensation (by IFN: HR = 0.313, p = 0.004; by DAA: HR = 0.281, p < 0.001). The benefits of achieving SVR in terms of overall survival and hepatic decompensation remained significant in subgroups of patients with and without recurrence. Patients with SVR showed a significant decline in FIB‐4 score and a higher proportion of ALBI grade improvement. Among SVR patients, the IMbrave050 criteria predicted LTP but not distant recurrence, whereas the FIB‐4 score after SVR, rather than the baseline FIB‐4, predicted distant recurrence.
Conclusions
HCV eradication was associated with a significant reduction in distant recurrence, mortality and hepatic decompensation following RFA in patients with HCV‐related HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
- Division of Gastroenterology and Hepatology, Department of Medicine, Keelung Hospital, Ministry of Health and Welfare, Keelung, Taiwan.
- School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan.
- Healthcare and Service Center, Taipei Veterans General Hospital, Taipei, Taiwan.
ORCID-Profile: Kuo-Cheng Wu, I-Cheng Lee, Jiing-Chyuan Luo, Yi-Hsiang Huang
Förderung
- Ministry of Science and Technology, Taiwan
- Taipei Veterans General Hospital
- National Science and Technology Council
Zitieren
APA
Wu, K. C., Lee, I. C., Chi, C. T., Liu, C. A., Chiu, N. C., Hsu, S. J., Lee, P. C., Wu, C. J., Luo, J. C., Hou, M. C., & Huang, Y. H. (2024). Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation. Alimentary Pharmacology & Therapeutics, 60(7), 940-952. https://doi.org/10.1111/apt.18199
Vancouver
Wu KC, Lee IC, Chi CT, Liu CA, Chiu NC, Hsu SJ, et al. Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation. Alimentary Pharmacology & Therapeutics. 2024;60(7):940-952. doi:10.1111/apt.18199
BibTeX
@article{Wu2024,
author = {Wu, Kuo-Cheng and Lee, I-Cheng and Chi, Chen-Ta and Liu, Chien-An and Chiu, Nai-Chi and Hsu, Shao-Jung and Lee, Pei-Chang and Wu, Chi-Jung and Luo, Jiing-Chyuan and Hou, Ming-Chih and Huang, Yi-Hsiang},
title = {Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV ‐related hepatocellular carcinoma undergoing radiofrequency ablation},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {7},
pages = {940--952},
doi = {10.1111/apt.18199}
}
EUVIMED